Fluorine-18-CTT 1057

Drug Profile

Fluorine-18-CTT 1057

Alternative Names: 18F CTT1057; CTT 1057 18F; CTT 1057 F18; CTT1057

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Targeted Technology
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 28 Aug 2017 Cancer Targeted Technology and University of California completes a phase I trial in Prostate cancer (Diagnosis; Metastatic disease; Late-stage disaese) in USA (IV) (NCT02916537)
  • 02 Jun 2017 Interim efficacy data from a phase I trial in Prostrate cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 03 Jun 2016 Safety data from a preclinical study in Prostate cancer was presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top